Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
187 hedge funds and large institutions have $2.74B invested in Intra-Cellular Therapies Inc. in 2021 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 57 increasing their positions, 68 reducing their positions, and 14 closing their positions.
243% more call options, than puts
Call options by funds: $39M | Put options by funds: $11.4M
121% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 14
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
19% more capital invested
Capital invested by funds: $2.3B → $2.74B (+$432M)
10% more funds holding
Funds holding: 170 → 187 (+17)
16% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 68
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$9.86M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$9.71M |
| 3 |
Morgan Stanley
New York
|
+$8.32M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$7.25M |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$7.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$16.2M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$12.6M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$9.98M |
| 4 |
SC
Samlyn Capital
New York
|
-$8.94M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.39M |
ITCI Hedge Fund Activity: Q2 2021 in Review
187 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2021, worth a combined $2.74B — up 19% from $2.3B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ITCI positions and 14 closed out — a net gain of 17 holders — while 57 added to existing stakes and 68 trimmed.
The largest buyer was Skandinaviska Enskilda Banken (SEB), adding an estimated $9.86M. The largest seller was BlackRock, cutting an estimated $16.2M.
- 187 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2021, up from 170 in Q1 2021.
- Funds reported $2.74B of Intra-Cellular Therapies Inc. stock for Q2 2021, up 19% quarter-over-quarter.
- 31 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2021 and 14 closed out, a net change of +17 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q2 2021 was Skandinaviska Enskilda Banken (SEB), an estimated $9.86M added.
- The largest Intra-Cellular Therapies Inc. seller in Q2 2021 was BlackRock, an estimated $16.2M sold.
Based on aggregated 13F filings for Q2 2021.